Skip to main content
MEHA
NASDAQ Life Sciences

Functional Brands Faces Going Concern Doubt, Nasdaq Delisting Risk, and Material Weaknesses in Annual Report

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.159
Mkt Cap
$2.524M
52W Low
$0.13
52W High
$8
Market data snapshot near publication time

summarizeSummary

Functional Brands Inc. disclosed significant financial challenges in its annual report, including a going concern warning, Nasdaq delisting risk, and multiple material weaknesses in internal controls, despite a net income driven by non-operating gains.


check_boxKey Events

  • Going Concern Doubt

    The independent auditor expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and an accumulated deficit of $6.98 million.

  • Nasdaq Delisting Warning

    The company received a deficiency letter from Nasdaq on December 30, 2025, for failing to meet the $1.00 minimum bid price requirement, with a compliance deadline of June 29, 2026. A reverse stock split is being considered.

  • Material Weaknesses in Internal Controls

    Management identified seven material weaknesses in internal control over financial reporting as of December 31, 2025, including issues with management override of controls, financial reporting expertise, revenue recognition, preferred stock accounting, inventory allowance, contractual compliance, and expense accrual.

  • Preferred Stock Restructuring

    On March 13, 2026, the company exchanged Series A and B Convertible Preferred Stock for newly issued Series C Convertible Preferred Stock, cash, and senior secured convertible promissory notes bearing 12% interest. The Series C is convertible at fixed prices of $0.30, $0.35, and $0.41 per share.


auto_awesomeAnalysis

Functional Brands Inc.'s annual report reveals significant financial distress and operational challenges. The auditor has expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses, negative cash flows, and a substantial accumulated deficit. The company also faces a Nasdaq delisting risk due to its common stock trading below the $1.00 minimum bid price, with a potential reverse stock split being considered. Furthermore, management identified seven material weaknesses in internal controls over financial reporting, indicating severe deficiencies in financial oversight. While the company reported a net income for 2025, this was primarily driven by non-operating gains from derivative liabilities and an ERTC refund, masking a significant increase in operating losses. The recent restructuring of preferred stock, while addressing complex liabilities, introduces new Series C convertible preferred stock and senior secured convertible notes with a high 12% interest rate, reflecting a high cost of capital. Investors should be highly cautious given the existential risks and internal control issues.

At the time of this filing, MEHA was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.13 to $8.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed MEHA - Latest Insights

MEHA
Apr 27, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
MEHA
Apr 22, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
7
MEHA
Apr 13, 2026, 4:10 PM EDT
Filing Type: PRE 14A
Importance Score:
9
MEHA
Mar 30, 2026, 10:14 AM EDT
Filing Type: 8-K
Importance Score:
9
MEHA
Mar 27, 2026, 5:08 PM EDT
Filing Type: 10-K
Importance Score:
9
MEHA
Mar 20, 2026, 8:00 AM EDT
Source: TMX Newsfile
Importance Score:
7
MEHA
Mar 13, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
MEHA
Feb 23, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
MEHA
Feb 06, 2026, 8:12 PM EST
Filing Type: 8-K
Importance Score:
8
MEHA
Feb 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8